About Relmada
Relmada is a company based in Blue Bell (United States) founded in 2007. Relmada has raised $12.96 million across 9 funding rounds from investors including BioAdvance and Ben Franklin Technology Partners. The company has 17 employees as of December 31, 2024. Relmada offers products and services including NDV-01. Relmada operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Blue Bell, United States
- Employees 17 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Relmada Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$79.98 M (USD)19.04as on Dec 31, 2024
-
EBITDA
-$83.89 M (USD)19.1as on Dec 31, 2024
-
Total Equity Funding
$12.96 M (USD)
in 9 rounds
-
Latest Funding Round
$825.75 K (USD), Post-IPO
Oct 08, 2019
-
Investors
BioAdvance
& 1 more
-
Employee Count
17
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Relmada
Relmada is a publicly listed company on the NASDAQ with ticker symbol RLMD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Relmada
Relmada offers a comprehensive portfolio of products and services, including NDV-01.
Drug for treating High-Grade Non-Muscle Invasive Bladder Cancer
People of Relmada
Unlock access to complete
Unlock access to complete
Funding Insights of Relmada
Relmada has successfully raised a total of $12.96M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $825.75 thousand completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Relmada
Relmada has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include BioAdvance and Ben Franklin Technology Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Technology ecosystem growth is supported in Southeastern Pennsylvania.
|
Locked | Locked | Locked |
Investor details for Relmada
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Relmada
Investment portfolio details for Relmada
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Relmada
Detailed financials for Relmada
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Relmada Comparisons
Peer comparison for Relmada
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Relmada
Relmada operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Relmada
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Relmada
Complete news archive for Relmada
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Relmada
Relmada was founded in 2007 and raised its 1st funding round 6 years after it was founded.
Relmada is headquartered in Blue Bell, United States. It is registered at Blue Bell, Pennsylvania, United States.
Relmada is a funded company, having raised a total of $12.96M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Relmada is 17.
Relmada Therapeutics is a clinical-stage, publicly-traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities for the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse-resistant, sustained release dosage form of the opioid analgesic levorphanol.
Relmada's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Biohaven Pharmaceutical.
Relmada offers NDV-01.
Yes, Relmada is publicly traded on NASDAQ under the ticker symbol RLMD.
Relmada has 2 investors. Key investors include BioAdvance, and Ben Franklin Technology Partners.
The ticker symbol of Relmada is RLMD on NASDAQ.